On June 12, 2017, the United States Supreme Court issued its first ruling on two key provisions of the Biologics Price Competition and Innovation Act (“BPCIA”) concerning the resolution of patent infringement suits in connection with the submission to the Food and Drug Administration (“FDA”) of applications to commercialize biosimilars in the United States.1
To view the entire article please visit here.
Need any tips on protecting your company's data? Please watch the below webinar hosted by Lucas Beal. Should you have any questions or...
With the expansion of cryptocurrency and the opportunities to capitalize on its growth, there has been a recent flurry of sponsors...
The New York State Commissioner of Health (“Commissioner”) has extended the designation of COVID-19 as a “highly contagious communicable...
留言